Abstract
The efficacy and toxicity of aminoglycosides show a strong direct positive relationship with blood drug concentrations, therefore, therapy with aminoglycosides in adults is usually guided by therapeutic drug monitoring. Dosing regimens in adults have evolved from multiple daily dosing to extended-interval dosing. This evolution has also taken place in neonates. Neonates, however, display large interindividual differences in the pharmacokinetics of aminoglycosides due to developmental differences early in life. The volume of distribution of aminoglycosides shows a strong relationship with bodyweight, which tends to be larger (corrected for bodyweight) in more premature infants and those with sepsis. Renal clearance of aminoglycosides increases with gestational age and accelerates immediately after birth. Because of these developmental influences, there is great inter- and intraindividual variability in the volume of distribution and clearance of these drugs, and investigators have established aminoglycoside dosing regimens based on bodyweight and/or gestational age. Widely practised dosing regimens comprise 4–5 mg/kg bodyweight of gentamicin every 24–48 hours as a first dose, followed by dose adjustment based on therapeutic drug monitoring. Although formal toxicity studies are scarce, there is no evidence that aminoglycoside toxicity in neonates differs from that in adults. Monitoring of blood drug concentrations and intelligent reconstruction of individual pharmacokinetic behaviour using a population pharmacokinetic model, optimally chosen blood sampling times and appropriate pharmacokinetic software, help clinicians to quickly optimize aminoglycoside dosing regimens to maximize the clinical effect and minimize the toxicity of these drugs.
Similar content being viewed by others
References
Trijbels-Smeulders M, Gerards LJ, Paskerde Jong PCM, et al. Epidemiology of neonatal group B streptococcal disease in the Netherlands. 1997–98. Pediatr Perinat Epidemiol 2002; 16(4): 334–41
Fanos V, Dall’Agnola A. Antibiotics in neonatal infections. Drugs 1999; 58: 406–27
Mingeot-LeClercq M-P, Glupczynski Y, Tulkens P. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999; 43: 727–37
Noone P, Parsons TMC, Pattison JR, et al. Experience in monitoring gentamicin therapy during treatment of serious Gram-negative sepsis. Br Med J 1974; 1:477–81
Anderson ET, Young LS, Hewitt WL. Simultaneous antibiotic levels in “breakthrough” Gram-negative rod bacteremia. Am J Med 1976; 61: 493–7
Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med 1984; 77: 657–62
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–9
Lorian V. Antibiotics in laboratory medicine. 4th ed. Baltimore (MD): Williams and Wilkins, 1996
Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650–5
Lundergan FS, Glasscock GF, Kim EH, et al. Once-daily gentamicin dosing in newborn infants. Pediatrics 1999; 103: 1228–34
Stickland MD, Kirkpatrick CMJ, Begg EJ, et al. An extended interval dosing method for gentamicin in neonates. J Antimicrob Chemother 2001; 48: 887–93
Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35: 117–23
Mingeot-LeClercq M-P, Tulkens P. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999; 43: 1003–12
Lehly DJ, Braun BI, Tholl DA, et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrol 1994; 8: 81–90
Giuliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236: 470–5
Rougier F, Ducher M, Maurin M, et al. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet 2003; 52: 493–500
Brummett RE, Fox KE. Aminoglycoside-induces hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 797–800
Scheenstra J, Heijerman HG, Touw DJ, et al. Cochleotoxicity of systemically administered tobramycin in cystic fibrosis patients [abstract]. J Cyst Fibros 2007; 6 Suppl. 1:94
Smith PF. Are vestibular hair cells excited to death by aminoglycoside antibiotics? J Vest Res 2000; 10: 1–5
Leung JC, Marphis T, Craver RO, et al. Altered NMDA receptor expression in renal toxicity: protection with a receptor antagonist. Kidney Int 2004; 66: 167–76
Chattopadhyay B. Newborns and gentamicin: how much and how often? J Antomicrob Chemother 2002; 49: 13–6
Dahlgren JG, Anderson ET, Hewitt WL. Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother 1975; 8: 58–62
Godman EL, Van Gelder J, Holmes R, et al. Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin. Antimicrob Agents Chemother 1975; 8: 434–8
Barclay ML, Kirkpatrick CMJ, Begg EJ. Once daily aminoglycoside therapy: is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999; 36: 89–98
Koren G. Therapeutic drug monitoring principles in the neonate. Clin Chem 1997; 43: 222–7
Touw DJ, Bos JM. Development of gentamicin population parameters in pediatric patients [abstract]. Ther Drug Monit 1997; 19: 570
Stolk LML, Degraeuwe PLJ, Nieman FHM, et al. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit 2002; 24: 527–31
Allegaert K, Anderson BJ. Interindividual variability of aminoglycoside pharmacokinetics in preterm neonates at birth. Eur J Clin Pharmacol 2006; 62: 1011–2
Contrepois A, Brion N, Garaud JJ, et al. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. Antimicrob Agents Chemother 1985; 27: 520–4
Besunder JB, Reed MD, Blumer JL. Principles of drug disposition in the neonate: a critical evaluation of the pharmacokinetic-pharmacodynamic interface (part 1). Clin Pharmacokinet 1988; 14: 189–216
Sum BL, Veltkamp SA, Westerman EM, et al. An extended-interval gentamicin dosing regimen in newborns: a prospective study. Eur J Hosp Pharm Science 2007; 13:98–104
Allegaert K, Anderson BJ, Van den Anker J, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit 2007; 29: 284–91
Van den Anker JN. Pharmacokinetics and renal function in preterm infants. Acta Paediatr 1996; 85: 1393–9
Veltkamp SA, Westerman EM, Sprij AJ, et al. Gentamicin in preterm neonates: an extended interval dosing schedule. Eur J Hosp Pharm Science 2007; 13:92–7
Faura CC, Garcia MR, Horga JF. Changes in gentamicin serum levels and pharmacokinetic parameters in the newborn in the course of treatment with aminoglycoside. Ther Drug Monit 1991; 13: 277–80
Vervelde ML, Rademaker CMA, Krediet TG, et al. Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen. Ther Drug Monit 1999; 21: 514–9
Gal P, Gilman JT. Drug disposition in neonates with patent ductus arteriosus. Ann Pharmacother 1993; 27: 1383–8
Williams BS, Ransom JL, Gal P, et al. Gentamicin pharmacokinetics in neonates with patent ductus arteriosus. Crit Care Med 1997; 25: 273–5
Touw DJ, Proost JH, Stevens R, et al. Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus. Pharm World Sc 2001; 23: 200–4
Allegaert K, Andersen BJ, Cossey V, et al. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 2006; 61: 39–48
Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet 2003; 42: 403–17
Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1989; 33: 817–9
Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1992; 12: 28–32
Dodge WF, Jelliffe RW, Zwischenberger JB, et al. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994; 16: 552–9
Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990; 19: 280–318
Dodge WA, Jelliffe RW, Richardson CJ, et al. Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method. Clin Pharmacol Ther 1991; 50: 25–31
Jensen PD, Edgren BE, Brundage RC. Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed effects model. Pharmacotherapy 1992; 12: 178–82
Rocha MJ, Almeida AM, Afonso E, et al. The kinetic profile of gentamicin in premature neonates. J Pharm Pharmacol 2000; 52: 1091–7
Lanao JM, Calvo MV, Mesa JA, et al. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. J Antimicrob Chemother 2004; 54: 193–8
Garciá B, Barcia E, Pérez F, et al. Population pharmacokinetics of gentamicin in premature neonates. J Antimicrob Chemother 2006; 58: 372–9
Rocha MJ, Almeida A, Falcao AC. Retrospective evaluation of gentamicin dosage guidelines for premature neonates. Eur J Hosp Pharm Science 2006; 12: 16–8
Ariano RE, Sitar DS, Davi M, et al. Bayesian pharmacokinetic analysis of a gentamicin nomogram in neonates: a retrospective study. Curr Ther Res 2003; 64: 178–88
Falcao AC, Santos Buelga D, Méndez ME, et al. Population kinetics of tobramycin in neonates. Ther Drug Monit 2001; 23: 202–8
De Hoog M, Mouton JW, Schoemaker RC, et al. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. Clin Pharmacol Ther 2002; 71: 349–58
Tréluyer J-M, Merlé Y, Semlali A, et al. Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method. Clin Pharmacol Ther 2000; 67: 600–9
Kenyon CF, Knoppert DC, Lee SK, et al. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother 1990; 34: 265–8
Izquierdo M, Lanao JM, Cervero L, et al. Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit 1992; 14(3): 177–83
De Hoog M, Schoemaker RC, Van den Anker JN, et al. NONMEM and NPEM2 population modelling: a comparison using tobramycin data in neonates. Ther Drug Monit 2002; 24: 359–65
Siegel JD, McCracken GH, Thomas ML, et al. Pharmacokinetic properties of netilmicin in newborn infants. Antimicrob Agents Chemother 1979; 15:246–53
Faura CC, Feret MA, Horga JF. Monitoring serum levels of gentamicin to develop a new regimen for gentamicin dosage in newborns. Ther Drug Monit 1991; 13: 268–76
De Hoog M, Schoemaker RC, Mouton JW, et al. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther 1997; 62: 392–9
Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2007; 114: 111–8
Gooding N, Elias-Jones A, Shenoy M. Gentamicin dosing in neonatal patients. Pharm World Sc 2001; 23: 179–80
Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmac 1995; 39: 605–9
Nesthaas E, Bangstad H-J, Sandvik L, et al. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch Dis Child Fetal Neonatal Ed 2005; 90: F294–300
Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380–93
Jelliffe R, Schumitzky A, Van Guilder M. Nonpharmacokinetic clinical factors affecting aminoglycoside therapeutic precision: a simulation study. Drug Invest 1992; 4:20–9
D’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739–56
Jelliffe RW, Iglesias T, Hurst AK, et al. Individualising gentamicin dosage regimens: a comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet 1991; 21: 461–78
Jelliffe RW. Clinical applications of pharmacokinetics and control theory: planning, monitoring, and adjusting dosages regimens of aminoglycosides, lidocaine, digitoxin and digoxin. In: Maronde R, editor. Selected topics in clinical pharmacology. New York: Springer Verlag, 1986: 26–82
Pons G, Tréluyer J-M, Dimet J, et al. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther Drug Monit 2002; 24: 9–14
Touw DJ, van Weissenbruch MM, Lafeber HN. The predictive performance of therapeutic drug monitoring (TDM) of amikacin in neonates using an early single determination of the serum concentration together with a population model [abstract]. Br J Clin Pharm 2000; 50: 487–8
Jelliffe RW, Tahani B. A library of serum drug assay error patterns, and some suggestions for improved modeling and simulation of pharmacokinetic behavior. Technical Report no: 92-5. Los Angeles (CA): USC School of Medicine, Laboratory of Applied Pharmacokinetics [online]. Available from URL: http://www.lapk.org/techreports.php [Accessed 2009 Jan 16]
Touw DJ, Neef C, Thomson AH, et al. Cost-effectiveness of therapeutic drug monitoring: an update. Eur J Hosp Pharm Sci 2007; 13: 83–91
Van Lent-Evers NAEM, Mathot RAA, Geus WP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999; 21: 63–73
El Desoky ES, Sheikh AA, Al Hammadi AY. Aminoglycoside and vancomycin serum concentration monitoring and mortality due to neonatal sepsis in Saudi Arabia. J Clin Pharm Ther 2003; 28: 479–83
De Hoog M, Van Zanten BA, Hop WC, et al. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003; 142: 41–6
Acknowledgements
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Touw, D.J., Westerman, E.M. & Sprij, A.J. Therapeutic Drug Monitoring of Aminoglycosides in Neonates. Clin Pharmacokinet 48, 71–88 (2009). https://doi.org/10.2165/00003088-200948020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200948020-00001